An interventional study of Sensory device and Skills Building in Functional Dyspepsia, sponsored by Spaulding Rehabilitation Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Spaulding Rehabilitation Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Dyspepsia with a site in United States — 14 open to participants now, 18 under way, 1 of them phase 3. Dyspepsia · United States.
Among the 77 studies in Dyspepsia with a site in United States, this one is the 21st largest by planned enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2025, is one of 34 with no phase, reaches primary completion later than 16 of the 17 other live ones, and was the 70th registered.
373 studies on the registry are indexed under Dyspepsia; 67 are open to participants now.
Browse Dyspepsia studies →14 of the 77 studies in Dyspepsia with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Hospital Universitari Vall d'Hebron Research Institute · Sites in United States, Canada, France and 4 more countries
Ages 18–80 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–80
NYU Langone Health · Sites in United States
Ages 21–65 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 13 · Phase 4 2
First in 1999; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 88 across 303 interventional studies indexed under Dyspepsia.
Median enrollment 50 across the 67 interventional studies, 41 across the 10 observational. Of the 52 that completed or were terminated, 14 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 77 have an industry lead sponsor. The 10 most frequent:
Spaulding Rehabilitation Hospital is the lead sponsor of 118 studies on the registry; 27 are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 17 (85%) have results posted.
Spaulding Rehabilitation Hospital has 1 study filed under Dyspepsia — fewer than ten, so there is no comparison to draw.
7 of the studies in Dyspepsia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT05836597Mayo ClinicFunctional Dyspepsia Treatment Using Virtual Reality | 2026-12 |
| NCT06941545Mayo ClinicHigh Resolution Gastric Mapping and Gastroduodenal Manometry | 2026-12-31 |
| NCT05653310Xiao Jing (Iris) WangTradipitant for Functional Dyspepsia | 2027-03 |
| NCT06369753Hospital Universitari Vall d'Hebron Research InstituteVisible Abdominal Distension | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 77 studies in Dyspepsia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims at evaluating physiological and patient-reported outcomes for a dual intervention approach including a stimulation device and support therapy in patients with functional dyspepsia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age 18-65 years old (inclusive)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Sensory device · Behavioral: Skills Building
Device: Sensory device · Behavioral: Health Education
Behavioral: Skills Building · Device: Subsensory device
Behavioral: Health Education · Device: Subsensory device
Sensory vagal nerve stimulation
Skills Building behavioral therapy
Education of FD condition
Subsensory vagal nerve stimulation
Visceral Sensitivity Index (VSI)
GI-related anxiety; score ranging from score ranging from 0 to 75, with higher scores indicating worse outcomes
Time frame: 8 weeks (post-treatment)
Gastric peristaltic velocity
MRI-derived gastric motility outcome
Time frame: 8 weeks (post-treatment)
Nepean Dyspepsia Index (NDI)
FD symptoms severity; score ranging from 0 to 100, with higher scores indicating worse outcomes
Time frame: 8 weeks (post-treatment)
Started Oct 2025 (actual). Primary completion is estimated for Mar 2030, 53 months after the start.
Of 71 non-industry interventional studies with no phase under Dyspepsia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 28. This study's planned 53 months is above that.
Counting every sponsor, half of 79 studies reached it within 17 months; a quarter within 9 and three quarters within 34.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Mar 2029 → Mar 2030 and completion Mar 2029 → Mar 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spaulding Rehabilitation Hospital →